The role of induction chemotherapy (IC) in locally advanced squamous cell carcinoma of the head/neck (LA-SCCHN) continues to be a controversial. While randomized trials have established that cisplatin/5-FU (PF) IC is equivalent to surgery followed by radiation therapy and may improve survival compared with chemoradiotherapy (CRT) for organ preservation, a definitive answer in locally advanced disease, outside of organ preservation, has been elusive [1–3]. The DeCIDE and Paradigm trials are considered to be negative IC trials exploring taxotere/cisplatin/5-FU (TPF) as IC, however both trials were inconclusive. They accrued poorly and failed to meet planned enrollment goals. Hence, the studies were underpowered and the results indeterminate [4, 5]. The GSTTC Italian Collaborative Group study in this issue of the Annals...

中文翻译：

---

意大利合作组织为治疗局部晚期头颈癌制定了标准。

诱导化学疗法（IC）在局部晚期头颈部鳞状细胞癌（LA-SCCHN）中的作用仍是一个有争议的问题。尽管随机试验已经确定，顺铂/ 5-FU（PF）IC等同于手术后进行放射治疗，并且与化学放疗（CRT）相比，其在器官保存方面的生存率更高，这是局部晚期疾病在器官保存之外的明确答案，一直难以捉摸[1-3]。DeCIDE和Paradigm试验被认为是阴性的IC试验，以紫杉醇/顺铂/ 5-FU（TPF）作为IC，但尚无定论。他们的成绩很差，未能达到计划的入学目标。因此，研究能力不足，结果不确定[4，5]。GSTTC意大利合作小组在本期《年鉴》中的研究...